v3.26.1
Significant Accounting Policies - Additional Information (Detail)
$ in Millions
6 Months Ended
Feb. 20, 2025
Jun. 30, 2026
Segment
shares
Dec. 31, 2025
shares
Aug. 29, 2025
USD ($)
Accounting Policy [Line Items]        
Common Stock, Shares, Outstanding | shares   4,049,000 4,047,000  
Common stock, shares authorized | shares   225,000,000 225,000,000  
Number of reportable segment | Segment   1    
Discontinued Operation, Name [Extensible Enumeration] FibroGen International [Member] FibroGen International [Member]    
Beijing Falikang Pharmaceutical Co Ltd | Beijing Kangda Yongfu Pharmaceutical Co., LTD [Member] | AstraZenecaAB [Member]        
Accounting Policy [Line Items]        
Percentage of outstanding shares acquired 51.10%     51.10%
Share Purchase Agreement [Member]        
Accounting Policy [Line Items]        
Discontinued operation consideration       $ 220.4
Share Purchase Agreement [Member] | FibroGen International [Member]        
Accounting Policy [Line Items]        
Discontinued operation consideration       220.4
Discontinued operation consideration in cash       85.0
Share Purchase Agreement [Member] | FibroGen International [Member] | CHINA        
Accounting Policy [Line Items]        
Discontinued operation consideration       220.4
Discontinued operation consideration in cash       85.0
Share Purchase Agreement [Member] | Net Cash Held in China [Member]        
Accounting Policy [Line Items]        
Discontinued operation consideration in cash       135.4
Share Purchase Agreement [Member] | Net Cash Held in China [Member] | CHINA        
Accounting Policy [Line Items]        
Discontinued operation consideration in cash       $ 135.4